Trending NewsTrending NewsNASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis $94.45 -4.01 (-4.07%) Closing price 04:00 PM EasternExtended Trading$93.88 -0.58 (-0.61%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kodiak Sciences Stock (NASDAQ:KOD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kodiak Sciences alerts:Sign Up Key Stats Today's Range$88.63▼$98.9550-Day Range$31.52▼$98.4652-Week Range$10.94▼$104.00Volume2.67 million shsAverage Volume1.12 million shsMarket Capitalization$5.94 billionP/E RatioN/ADividend YieldN/APrice Target$100.43Consensus RatingModerate Buy Company Overview Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye. Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Its principal investigational product, KSI-301, is an anti-VEGF-A therapy designed for longer-lasting activity than conventional treatments. Kodiak has also researched KSI-501, a potential dual-action therapy intended to target both VEGF-A and inflammatory pathways implicated in retinal disease. Founded in 2009, Kodiak has conducted clinical development activities in the United States and other international markets. The company is led by Victor Perlroth, M.D., who co-founded Kodiak and has served as its chief executive officer. Kodiak’s development programs remain focused on addressing the treatment burden associated with frequent intraocular injections for patients with retinal disorders.AI Generated. May Contain Errors. Read More Kodiak Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreKOD MarketRank™: Kodiak Sciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 661st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingKodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Kodiak Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKodiak Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kodiak Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.89) to ($4.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -22.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -22.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 31.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kodiak Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.54% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 17.87, which indicates bearish sentiment.Change versus previous monthShort interest in Kodiak Sciences has recently decreased by 1.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.59 News SentimentKodiak Sciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 65 news articles for Kodiak Sciences this week, compared to 6 articles on an average week.Search Interest19 people have searched for KOD on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.MarketBeat Follows12 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $156,986,026.00 in company stock, which represents 2.6763% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $156,986,026.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders44.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KOD Stock News HeadlinesKodiak Sciences consensus price target increased by 65.16% to $117.502 hours ago | msn.comKodiak Sciences (NASDAQ:KOD) Stock: Insider Bros. Advisors Lp Baker Purchases 33,726 SharesOctober 2 at 4:09 AM | americanbankingnews.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 2 at 1:00 AM | Base Camp Trading (Ad)Brokers Set Expectations for Kodiak Sciences FY2027 EarningsOctober 2 at 2:01 AM | americanbankingnews.comKodiak Sciences More Than Doubles on Eye Disease Trial ResultsOctober 1 at 7:22 PM | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Sees Unusually-High Trading Volume on Analyst UpgradeOctober 1 at 1:21 AM | americanbankingnews.comA $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?September 30 at 8:05 AM | 247wallst.com3 Small-Cap Biotechs With Binary Catalysts on the CalendarKodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.September 13, 2026 | marketbeat.comSee More Headlines KOD Stock Analysis - Frequently Asked Questions How have KOD shares performed this year? Kodiak Sciences' stock was trading at $27.96 at the beginning of the year. Since then, KOD shares have increased by 233.8% and is now trading at $93.3290. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) announced its earnings results on Thursday, August, 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.09. When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK). Company Calendar Last Earnings8/13/2026Today10/02/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KOD's financial health is in the Green zone, according to TradeSmith. KOD has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KOD CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees124Year Founded2009Price Target and Rating Average Price Target for Kodiak Sciences$100.43 High Price Target$145.00 Low Price Target$61.00 Potential Upside/Downside+6.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$229.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-273.23% Return on Assets-85.48% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book31.80Miscellaneous Outstanding Shares62,850,000Free Float34,944,000Market Cap$5.94 billion OptionableOptionable Beta2.02 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:KOD) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
